Open Access
Research
Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial Khai P Ng,1 Poorva Jain,2 Paramjit S Gill,2 Gurdip Heer,2 Jonathan N Townend,3 Nick Freemantle,4 Sheila Greenfield,2 Richard J McManus,5 Charles J Ferro1 To cite: Ng KP, Jain P, Gill PS, et al. Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial. BMJ Open 2016;6:e010519. doi:10.1136/bmjopen-2015010519 ▸ Prepublication history and additional material is available. To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015010519). Received 10 November 2015 Revised 5 January 2016 Accepted 1 February 2016
For numbered affiliations see end of article. Correspondence to Dr Charles Ferro; [email protected]
ABSTRACT Objectives: To determine whether low-dose spironolactone can safely lower arterial stiffness in patients with chronic kidney disease stage 3 in the primary care setting. Design: A multicentre, prospective, randomised, placebo-controlled, double-blinded study. Setting: 11 primary care centres in South Birmingham, England. Participants: Adult patients with stage 3 chronic kidney disease. Main exclusion criteria were diagnosis of diabetes mellitus, chronic heart failure, atrial fibrillation, severe hypertension, systolic blood pressure
Research
Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial Khai P Ng,1 Poorva Jain,2 Paramjit S Gill,2 Gurdip Heer,2 Jonathan N Townend,3 Nick Freemantle,4 Sheila Greenfield,2 Richard J McManus,5 Charles J Ferro1 To cite: Ng KP, Jain P, Gill PS, et al. Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial. BMJ Open 2016;6:e010519. doi:10.1136/bmjopen-2015010519 ▸ Prepublication history and additional material is available. To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015010519). Received 10 November 2015 Revised 5 January 2016 Accepted 1 February 2016
For numbered affiliations see end of article. Correspondence to Dr Charles Ferro; [email protected]
ABSTRACT Objectives: To determine whether low-dose spironolactone can safely lower arterial stiffness in patients with chronic kidney disease stage 3 in the primary care setting. Design: A multicentre, prospective, randomised, placebo-controlled, double-blinded study. Setting: 11 primary care centres in South Birmingham, England. Participants: Adult patients with stage 3 chronic kidney disease. Main exclusion criteria were diagnosis of diabetes mellitus, chronic heart failure, atrial fibrillation, severe hypertension, systolic blood pressure
